lisa_labSD said:Albumin binding above 99% is the whole reason weekly dosing works, and it is also why the trough matters more than the peak.
Bookmarking. The distinction being drawn above is the one nobody else makes. Taking it to my next appointment.
Clinical perspective, offered as context rather than as advice.
GFR trending upward on renal function — encouraging for those with mild CKD concerns:
Baseline eGFR: 72 → Month 6: 78 → Month 12: 87
The FLOW trial confirmed renal benefits of semaglutide: 24% reduction in kidney disease progression. My nephrologist is now actively recommending GLP-1 therapy for appropriate CKD patients. This could be a paradigm shift in nephrology.
Dr.PeteFamMed said:Steady state is the thing most people miss.
Filing a mild objection. Mild because I might be wrong; an objection because nobody has addressed the case that does not fit. The trial means are being read too generously in this thread. STEP populations were selected, supported, and titrated by protocol, and the real-world curves are consistently a few points worse. That difference is not noise, it is what happens when you remove the study infrastructure.
PeptideDetective — Independent Peptide Analytics
Community-driven peptide testing and vendor rating platform. Transparent results. Unbiased analysis. Trusted by thousands.
View ResultsDr.RenalNash said:FLOW is the relevant trial and it reported a meaningful reduction in kidney-disease progression and related death in people with type 2 diabetes and…
Kidney function labs on renal function — good news for anyone concerned about renal effects:
| Marker | Baseline | Month 6 | Ref Range |
|---|---|---|---|
| eGFR | 80 | 93 | >60 |
| Creatinine | 1.3 | 0.9 | 0.7-1.3 |
| BUN | 18 | 14 | 7-20 |
| UACR | 65 | 18 | <30 |
The FLOW trial demonstrated renal protective effects of semaglutide. My nephrologist is encouraged by the UACR improvement especially.